Welcome to our dedicated page for Sol Gel Technolg news (Ticker: SLGL), a resource for investors and traders seeking the latest updates and insights on Sol Gel Technolg stock.
Sol-Gel Technologies Ltd. (NASDAQ: SLGL) is a dermatology company whose news flow centers on clinical trial progress, regulatory milestones, licensing transactions and financial updates related to its topical drug products and pipeline. The company developed TWYNEO, a fixed-dose combination cream for acne vulgaris, and EPSOLAY, a benzoyl peroxide cream for inflammatory lesions of rosacea, and continues to report on ex-U.S. approvals and commercialization agreements for these products.
Recent Sol-Gel news highlights include updates on its pivotal Phase 3 clinical trial of SGT-610 (patidegib gel 2%) for Gorlin syndrome, including completion of patient enrollment and expectations for future top-line results. The company also issues releases on exploratory work to extend SGT-610 into high-frequency basal cell carcinoma and on compassionate-use cases in patients with PTCH1-mutated lesions. For SGT-210, a topical erlotinib candidate for Darier disease and other rare hyperkeratinization disorders, Sol-Gel has reported on Phase 1b proof-of-concept data, trial design decisions and plans for feasibility studies in additional indications.
Investors following SLGL news will also find announcements on Health Canada’s approval of EPSOLAY, new license agreements with partners such as Searchlight Pharma, Viatris and regional distributors, and a product purchase agreement with a subsidiary of Mayne Pharma for U.S. rights to EPSOLAY and TWYNEO. Periodic financial results releases provide detail on revenue from licensing and royalties, research and development spending on SGT-610 and SGT-210, cash runway expectations and capital market developments such as the company’s reverse share split and Nasdaq listing status.
This news page aggregates these company-issued updates and related coverage, making it easier to track Sol-Gel’s clinical, regulatory and commercial milestones over time for its dermatology portfolio and rare disease pipeline.
Sol-Gel (NASDAQ: SLGL) announced results after unblinding a vehicle-controlled Phase 1b proof-of-concept study of SGT-210 in Darier disease on Dec 17, 2025. The company reported that the study did not show differentiation between SGT-210 and vehicle on efficacy assessments, and will not advance SGT-210 to the next development stage in Darier disease. The company said it plans to pursue very small, low-cost feasibility studies of SGT-210 in other indications with stronger mechanistic rationale. Sol-Gel also reiterated its ongoing focus on completing the Phase 3 program for SGT-610 in Gorlin syndrome and preparatory activities for a potential Phase 3 program in high-frequency BCC, contingent on Gorlin Phase 3 success.
Sol-Gel (NASDAQ: SLGL) reported Q3 2025 results and corporate updates on November 20, 2025. Total revenue was $0.4M versus $5.4M year-ago. R&D expenses were $5.7M; net loss was $5.9M or $2.13 per share. Cash, equivalents and marketable securities totaled $20.9M, with a cash runway into Q1 2027.
Pipeline and corporate highlights: Health Canada approved EPSOLAY; Sol-Gel signed an Australia/New Zealand license with Viatris; company expects EPSOLAY launches in 2027 and TWYNEO launches in 2028. Sol-Gel anticipates partner-driven royalties growing to ~$10M by 2031. The pivotal Phase 3 trial of SGT-610 (Gorlin) is ongoing with top-line results expected in Q4 2026; company plans to pursue high-frequency BCC as an additional indication. Stage 1 results for SGT-210 are due in December 2025.
Sol-Gel Technologies (NASDAQ: SLGL) has received Health Canada approval for EPSOLAY®, a treatment for inflammatory lesions of rosacea in adults. The approval, granted on August 27, 2025, comes through Sol-Gel's partnership with Searchlight Pharma, their exclusive Canadian licensee.
Under the 2023 licensing agreement, Sol-Gel is eligible to receive up to $11 million in combined milestone payments for TWYNEO and EPSOLAY, plus tiered royalties on net sales. The company expects ex-U.S. territory launches to begin in 2027-2028, with potential EBITDA contribution reaching approximately $10 million annually by 2031.
Sol-Gel is currently conducting a Phase-3 trial of SGT-610 for Gorlin syndrome and a Phase-1b trial of SGT-210 for Darier disease, as the company shifts focus toward dermatological rare diseases.
Sol-Gel Technologies (NASDAQ: SLGL) reported Q2 2025 financial results and significant corporate updates. The company announced total revenue of $17.2 million, primarily from a $16 million product sale agreement with Mayne Pharma for U.S. rights to EPSOLAY and TWYNEO. The quarter resulted in a net income of $11.6 million, or $4.17 per share.
Key developments include completion of patient enrollment for the Phase-3 trial of SGT-610 for Gorlin Syndrome, with top-line results expected in Q4 2026. The company continues its Phase-1b trial of SGT-210 for Darier disease. Sol-Gel implemented a 10-for-1 reverse share split to maintain Nasdaq listing. The company's cash position of $24.2 million is expected to extend runway into Q1 2027.
Sol-Gel Technologies (NASDAQ: SLGL) has entered into a product purchase agreement with Mayne Pharma for the U.S. rights to EPSOLAY and TWYNEO. The deal will provide Sol-Gel with $16 million in two installments during 2025, extending their cash runway into Q1 2027.
The company will focus on developing SGT-610, a potential first-ever preventative treatment for basal cell carcinomas in Gorlin syndrome patients, with an estimated U.S. market potential of $400-500 million annually. The Phase III trial has achieved 80% patient enrollment, with top-line results expected in Q4 2026.
As of March 31, 2025, Sol-Gel reported $16.9 million in cash and equivalents. The company is also advancing SGT-210, a treatment for Darier disease with a market potential of $200-300 million, with 50% of patients having completed the Phase 1b trial.
Sol-Gel Technologies (NASDAQ: SLGL) has received a 180-day extension until May 19, 2025, to regain compliance with Nasdaq's minimum bid price requirement. The company has transferred from Nasdaq Global Market to Nasdaq Capital Market effective November 15, 2024. To maintain listing, Sol-Gel must achieve a closing bid price of at least $1.00 per share for a minimum of ten consecutive business days. The company is considering various options, including a potential reverse share split, to meet this requirement.
Sol-Gel Technologies (NASDAQ: SLGL) reported Q3 2024 financial results with total revenue of $5.4 million, primarily from licensing agreements, compared to $0.2 million in Q3 2023. The company reported a net loss of $0.4 million ($0.01 per share), improved from a $5.7 million loss in Q3 2023. Cash position stands at $29.2 million, expected to fund operations into Q1 2026.
Key developments include Mori Arkin's approval as interim CEO starting January 2025, transfer to Nasdaq Capital Market, and ongoing Phase 3 trial of SGT-610 for Gorlin Syndrome with 40+ active clinical sites. New licensing agreements for TWYNEO and EPSOLAY are expected to generate up to $3.7 million in milestone payments.
Sol-Gel Technologies (NASDAQ: SLGL) reported Q2 2024 financial results and provided corporate updates. Key highlights include:
- Cash runway extended into Q1 2026
- Ongoing Phase 3 trial of SGT-610 for Gorlin Syndrome with top-line results expected by Q2 2026
- Proof-of-concept study for SGT-210 in Darier disease ongoing
- New agreement with Padagis for generic Zoryve® Cream, enhancing cash position by ~$6 million
- License agreements signed for TWYNEO and EPSOLAY in Europe and South Africa
- Q2 2024 revenue: $5.4 million; Net income: $1.9 million ($0.07 per share)
- Cash balance: $30.5 million as of June 30, 2024
FAQ
What is the current stock price of Sol Gel Technolg (SLGL)?
What is the market cap of Sol Gel Technolg (SLGL)?
